Psychedelics Hit Dozens of Brain Receptors Beyond Serotonin

Psychedelics are experiencing a scientific renaissance, with clinical trials showing promise for depression, anxiety, PTSD, addiction, and cluster headaches. Understanding precisely how these compounds work at the molecular level is essential for designing safer, more effective therapeutics — and this large-scale study takes a major step forward.

Researchers screened 41 classical psychedelics drawn from three chemical families — tryptamines (like psilocybin), phenethylamines (like mescaline), and lysergamides (like LSD) — against 318 human G-protein-coupled receptors (GPCRs). LSD was further tested against more than 450 human kinases, providing one of the most comprehensive pharmacological profiles of any psychedelic compound to date.

The key finding: psychedelics are not selective serotonin 5-HT2A agonists. They exhibit potent and efficacious activity at virtually every serotonin, dopamine, and adrenergic receptor tested. Furthermore, multiple intracellular signaling transducers downstream of 5-HT2A were activated by these compounds, and each transducer pathway independently correlated with psychedelic-like behavioral effects in animal models.

This polypharmacology — the ability of a single drug to act on many targets simultaneously — may help explain why psychedelics produce such diverse and profound effects. It also opens new avenues for drug development: by isolating specific receptor interactions, researchers may be able to design compounds that retain therapeutic benefits while minimizing hallucinogenic effects or side effects.

A key caveat is that this study relied on in vitro receptor binding and activation assays, and the clinical relevance of each individual target interaction remains to be established in human trials. The complexity of multi-target pharmacology also makes it difficult to attribute specific therapeutic outcomes to specific receptors without additional mechanistic studies.